The Pathology Core provides a comprehensive resource for human tissue-based research that takes advantage of the unique tissue resources available at the Center. Acquisition and banking of human biologic specimens to be used in studying the causes, detection, prevention and treatment of cancer has become an indelible source for supporting basic and translational cancer research in various laboratories throughout the Center. The reliability of molecular data derived from new technology platforms ultimately requires an adequate supply of optimally procured, high quality tissue specimens. The Pathology Core at MSKCC has capacity to meet this challenge and is designed as an efficient and cost-effective means to facilitate tissue use, to assist investigators with expertise in oncologic pathology and to conduct tissue-associated experimentation. The Pathology Core also serves as a national resource, as evidenced by the over 1,000 samples from multiple tumor types that have been provided to the NCI-funded Cancer Genome Atlas initiative. The Histology service within the Core facilitates selection of appropriate specimens for tissue analyses and provides basic service of cutting, dissecting and staining of fresh frozen and formalin fixed, paraffin embedded tissue. It includes construction of tissue microarray blocks and laser capture microdissection for isolation of pure cell populations and tumor cell enrichment. The Core Immunohistochemistry service provides automated and manual staining of optimized monoclonal and polyclonal antibodies to be used in clinico-pathologic correlative studies. This service also develops protocols for new antibody characterizations by using cell lines, xenograft tissue and variety of antigen retrieval and detection systems. The services and collaborative work provided by the Pathology Core has supported the research of 116 investigators in the past year. During the past grant period the work of the Core has contributed to 1320 publications of researchers from 7 research programs.
The Pathology Core provides a comprehensive resource for human tissue-based research that takes advantage of the unique tissue resource available at the Center. The services that the Pathology Core provide are fundamental to the translational mission of the Center.
|Orlow, I; Satagopan, J M; Berwick, M et al. (2015) Genetic factors associated with naevus count and dermoscopic patterns: preliminary results from the Study of Nevi in Children (SONIC). Br J Dermatol 172:1081-9|
|Carey, Bryce W; Finley, Lydia W S; Cross, Justin R et al. (2015) Intracellular ?-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518:413-6|
|Mosher, C E; Given, B A; Ostroff, J S (2015) Barriers to mental health service use among distressed family caregivers of lung cancer patients. Eur J Cancer Care (Engl) 24:50-9|
|Navi, Babak B; Reiner, Anne S; Kamel, Hooman et al. (2015) Association between incident cancer and subsequent stroke. Ann Neurol 77:291-300|
|Xu, Zhe; Wu, Chaochao; Xie, Fang et al. (2015) Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res 14:422-33|
|Xu, Hong; Cheng, Ming; Guo, Hongfen et al. (2015) Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 3:266-77|
|Gondo, Tatsuo; Poon, Bing Ying; Matsumoto, Kazuhiro et al. (2015) Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int 115:81-6|
|Ripley, R Taylor; McMillan, Robert R; Sima, Camelia S et al. (2014) Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma. Ann Thorac Surg 98:968-74|
|Ye, Jiangbin; Fan, Jing; Venneti, Sriram et al. (2014) Serine catabolism regulates mitochondrial redox control during hypoxia. Cancer Discov 4:1406-17|
|Lu, Zhigang; Xu, Jin; Xu, Mingming et al. (2014) Morphine regulates expression of *-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the *-opioid receptor (OPRM1) gene via miR-103/miR-107. Mol Pharmacol 85:368-80|
Showing the most recent 10 out of 836 publications